Literature DB >> 1505617

Population pharmacokinetics of imipramine in children.

M Tamayo1, M M Fernández de Gatta, M J García, A Domínguez-Gil.   

Abstract

The population pharmacokinetics of imipramine (IMI) and its active metabolite desipramine (DMI) have been evaluated using 177 IMI and DMI serum levels from 49 enuretic children (6-13 y) on IMI treatment. Standard two stage (STS) and maximum likelihood (ML) methods were used to estimate fixed and random effect parameters of IMI. Simultaneous estimation of the drug and metabolite parameters was carried out by the STS method. The mean value of the elimination constant of the drug and metabolite were 0.0425 h-1 and 0.0359, h-1 respectively. Significantly higher variability was found in the pharmacokinetic parameters of the metabolite. According to these estimated pharmacokinetic parameters, the recommended dose for enuretic children should be 1.7 mg.kg-1.day-1. The population pharmacokinetic parameters obtained in the study permit dosage individualisation using a bayesian algorithm.

Entities:  

Keywords:  Age Factors; Biology; Child; Clinical Research; Delivery Of Health Care; Demographic Factors; Depression--prevention and control; Developed Countries; Diseases; Drugs--pharmacodynamics; Europe; Examinations And Diagnoses; Health; Health Facilities; Hematologic Tests; Laboratory Examinations And Diagnoses; Laboratory Procedures; Mediterranean Countries; Mental Disorders; Methodological Studies; Outpatient Clinic; Physiology; Population; Population Characteristics; Research Methodology; Southern Europe; Spain; Treatment; Urogenital Effects; Urogenital System; Youth

Mesh:

Substances:

Year:  1992        PMID: 1505617     DOI: 10.1007/bf02280761

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  The population pharmacokinetics of theophylline in neonates and young infants.

Authors:  E S Moore; R G Faix; R C Banagale; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

3.  An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.

Authors:  K Yamaoka; H Tanaka; K Okumura; M Yasuhara; R Hori
Journal:  J Pharmacobiodyn       Date:  1986-02

4.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

5.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

6.  Plasma levels of imipramine and metabolites in 68 hospitalized children.

Authors:  S H Preskorn; S J Bupp; E B Weller; R A Weller
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1989-05       Impact factor: 8.829

7.  Prediction of imipramine serum levels in enuretic children by a Bayesian method: comparison with two other conventional dosing methods.

Authors:  M M Fernández de Gatta; M Tamayo; M J García; D Amador; F Rey; J R Gutiérrez; A Domínguez-Gil Hurlé
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681

8.  Imipramine in prepubertal major depressive disorders.

Authors:  J Puig-Antich; J M Perel; W Lupatkin; W J Chambers; M A Tabrizi; J King; R Goetz; M Davies; R L Stiller
Journal:  Arch Gen Psychiatry       Date:  1987-01

9.  Population pharmacokinetics of procainamide from routine clinical data.

Authors:  T H Grasela; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

10.  Targeting imipramine dose in children with depression.

Authors:  F Sallee; R Stiller; J Perel; M Rancurello
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

View more
  4 in total

1.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

Review 2.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

3.  Antidepressants, sex steroids and pituitary-adrenal response in sheep.

Authors:  Jillian H Broadbear; Thao Nguyen; Iain J Clarke; Benedict J Canny
Journal:  Psychopharmacology (Berl)       Date:  2004-03-03       Impact factor: 4.530

Review 4.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.